| Description |
People with psoriatic arthritis routinely rate their disease severity less favorably than their providers (Krueger, 2001) (Baughman, 2011). Little is known about how patients and providers perceive response to therapy. Discrepancies in perceptions of therapy response may indicate that providers are not adequately measuring the aspects of disease that are meaningful to patients. Insufficient assessments of disease states may lead to non‐ideal therapies and may contribute to patient noncompliance. In this study, patient and provider assessments of response to therapy were compared. Analysis of unseen reasons for discrepancy between ratings was exhibited based on patient responses to study forms. In the Psoriatic Research Consortium (PARC) study at the University Of Utah School Of Medicine, participants and their providers' rated response to therapy on a 4 point scale (Very well, Moderately well, A little, Not at All). Among participant groups with discrepant and non‐discrepant ratings, social and environmental factors are compared including aspects of depression and anxiety, quality of life, social and family participation, and work disability. Social and emotional factors are examined by an accumulation of questions measured by common questionnaires such as the HAQ, SF‐12, Work/Employment, PsAQuOL and the PSAID. Work disability will be measured by the WPAI. Outcome, exposure, and covariate variables are analyzed in congruence with disease features. We hypothesized that providers' rate response to therapy more favorably than participants. In addition, we hypothesized that participants with lower socioeconomic status (income and education), lower quality of life, and iii higher work disability will had less favorable therapy response ratings than providers, since these variables may not be adequately incorporated into provider assessments. However, results were null and no significant differences were made between the factors compared. These results suggest that future research in order to prove that a standardized patient assessment of therapy should be integrated into therapy decision making in routine clinical care. |
